Cognitive Dysfunction in Major Depressive Disorder

Limitations exist in identifying patients with major depressive disorder (MDD) and cognitive impairment, despite a majority of MDD patients exhibiting cognitive symptoms. Cognitive dysfunction also affects patient functional outcomes, including workforce performance and psychosocial interactions. Emerging agents, including multimodal antidepressants, show a promising direct effect on improving cognitive impairment in patients with MDD. Increased knowledge on diagnosis, treatment, long-term management, and integration of emerging treatment options into clinical practice will allow physicians to select appropriate treatment strategies and improve outcomes for patients with MDD and cognitive dysfunction.

Major Depressive Disorder: Getting the Patient Back to Work
Dr Goodwin and experts explore how recovery from major depressive disorder affects patients and the workplace.

November 23, 2016
Major Depressive Disorder: The Challenging Patient and the Goal of Recovery
Drs Vieta and Bromley discuss 3 challenging cases of cognitive dysfunction in MDD.

June 9, 2016
Using Cognitive Rating Scales in Major Depressive Disorder in Clinical Practice
Drs Harrison, Bromley, and Vieta discuss the practical applications for rating scales to measure cognition in major depressive disorder.

May 4, 2016

Steering Committee Chair

Guy M. Goodwin, FMedSci
Professor of Psychiatry,
Department of Psychiatry,
University of Oxford,
Oxford, United Kingdom

Steering Committee Members

John Harrison, CSci, CPsychol
Associate Professor,
Alzheimer Center,
VU University Medical Center,
Amsterdam, The Netherlands
Siegfried Kasper, MD
Professor and Chair,
Department of Psychiatry
and Psychotherapy,
Medical University of Vienna,
Vienna, Austria
Raymond W. Lam, MD, FRCPC
Professor and Associate
Head for Research,
Department of Psychiatry,
University of British Columbia;
Director, Mood Disorders Centre,
UBC Hospital, Vancouver Coastal Health;
Executive Chair, Canadian Network for
Mood and Anxiety Treatments (CANMAT),
Vancouver, British Columbia, Canada

Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and
Pharmacology, University of
Toronto; Head, Mood Disorders
Psychopharmacology Unit, University
Health Network, Toronto,
Ontario, Canada
David J. Nutt, MD, PhD
Edmund J. Safra Professor
of Neuropsychopharmacology;
Head, Centre for Neuropsychopharmacology,
Imperial College London,
London, United Kingdom

Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.

Supported by an independent educational
grant from

Downloadable Slide Kit

Cognitive Dysfunction in Major Depressive Disorder: Burden, Diagnosis And Management
An overview of the cognitive domain of depression, from societal impact to assessment scales, and therapeutic approaches.
Cognitive Dysfunction in Major Depressive Disorder
An overview of the effect of cognitive dysfunction on functional outcomes in patients with MDD and results with antidepressant therapy.

Clinical Articles

Steering Committee

Guy M. Goodwin, FMedSci

Guy M. Goodwin, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cephalon, Inc.; GlaxoSmithKline; Janssen-Cilag; Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Otsuka Pharmaceutical Co., Ltd.; P1vital; Roche; SERVIER; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc.
Received grants for clinical research from: SERVIER
Owns stock, stock options, or bonds from: P1vital
Served as an expert witness for: Eli Lilly and Company

John Harrison, CSci, CPsychol

John Harrison, CSci, CPsychol, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Anavex Life Sciences Corp.; AstraZeneca Pharmaceuticals LP; Avraham Pharmaceuticals; AXON; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bracket Global; Catenion; CRF Health; Dendron UK; Eisai Co., Ltd; Eli Lilly and Company; EnVivo Pharmaceuticals; ePharmaSolutions; Heptares; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kyowa Hakko Kirin Co., Ltd.; Lundbeck, Inc.; MedAvante; Mind Agilis; MyCognition; Neurocog; Novartis Pharmaceuticals Corporation; Nutricia; Orion Corporation; Pfizer Inc; Prana Biotechnology; Pricespective; ProStrakan, Inc.; Reviva Pharmaceuticals Inc; Roche; SERVIER; Shire; TCG; TransTech Pharma; UCB Pharma, Inc.; Velacor
Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.
Employed by a commercial interest: Metis Cognition Ltd

Siegfried Kasper, MD

Siegfried Kasper, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Angelini; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, L.P.; Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pfizer Inc; Pierre Fabre; Schwabe Pharmaceuticals; Sepracor Inc.; SERVIER; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Angelini; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, L.P.; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pierre Fabre; Schwabe Pharmaceuticals; SERVIER; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Lundbeck, Inc.

Raymond W. Lam, MD, FRCPC

Raymond W. Lam, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Lundbeck, Inc.; Pfizer Inc; Takeda Pharmaceuticals North America, Inc.; The Litebook Company
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lundbeck, Inc.; Mochida; Pfizer Inc; SERVIER
Received grants for clinical research from: Bristol-Myers Squibb Company; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc; St. Jude Medical; The Litebook Company

Roger S. McIntyre, MD, FRCPC

Roger S. McIntyre, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Organon Pharmaceuticals USA Inc.; Pfizer Inc; Shire
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck, Inc.; Pfizer Inc; Shire

David J. Nutt, MD, PhD

David J. Nutt, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceuticals Products, L.P.; Lundbeck, Inc.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Pfizer Inc; SERVIER
Received grants for clinical research from: GlaxoSmithKline; Lundbeck, Inc.